Scalper1 News
Biotech startup Bluebird Bio (BLUE) tumbled more than 20% Thursday after the company’s treatment for a genetic form of anemia produced disappointing trial results. Bluebird will present results from six studies of its lead product LentiGlobin BB305 at the American Society of Hematology conference next month, and on Thursday the abstracts of those and other presentations were released to the public. LentiGlobin deploys gene therapy to treat sickle Scalper1 News
Scalper1 News